Alyftrek 10-50-125 MG tablet 14S
Ended Awarded
- Contract number
- SPE2DB26FX1JY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,973
Award facts
- Contract value 100% obligated
- $83,973.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $83,973.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for ALYFTREK 10-50-125 mg tablets in quantities of 14. The award, issued on October 17, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to support the Department of Defense's pharmaceutical supply needs.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its extensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support military healthcare facilities worldwide. The company's PPV-G GEN V master contract, valued at $499,999,999 with a completion date of December 31, 2036, comprises a 30-month base period and three 30-month option periods, positioning DMS Pharmaceutical Group to fulfill the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations globally through firm fixed-price delivery orders.
Quick answers
Who was awarded contract SPE2DB26FX1JY?
SPE2DB26FX1JY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 17, 2025.
How much is contract SPE2DB26FX1JY worth?
The government has obligated $83,973 on SPE2DB26FX1JY.
Is contract SPE2DB26FX1JY an order under another contract?
Yes. SPE2DB26FX1JY is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1JY competed?
The extent of competition for SPE2DB26FX1JY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award